Antileukotrienes in allergic diseases in children;Leki przeciwleukotrienowe w chorobach alergicznych u dzieci

Polski Merkuriusz Lekarski

Volumn 14, Issue 84, 2003, Pages 631-633

  Jung, Anna ^a  

^a NONE

Author keywords

Asthma; Leukotriene antagonist; Montelucast

Indexed keywords

ANTIHISTAMINIC AGENT; BUDESONIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PEPTIDOLEUKOTRIENE;

ALLERGIC ASTHMA; ALLERGIC DISEASE; BRONCHUS; CHILD; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; INFLAMMATION; MEDICAL LITERATURE; REVIEW;

EID: 0038444361     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Aharony D.: Pharmacology of leukotriene receptor antagonists. Am. J. Respir. Crit. Care Med., 1998, 157, 214-219.
2. Barnes P.: Current therapy for asthma. Promise and limitations. Chest. 1997, 111, 17-26.
3. Bjermer L., Diamant Z.: The use of leukotriene receptor antagonists as complementary therapy in asthma. Monaldi Arch. Chest. Dis., 2002, 57, 76-83.
4. Bisgaard H. i wsp.: NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am. J. Respir. Crit. Care Med., 1999, 160, 1227.
5. Bisgaard H.: Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma. Allergy, 2001, 56, suppl. 66, 7-11.
6. Bisgaard H., Nielsen H.G.: Bronchoprotection from leukotriene receptor antagonist in asthmatic pre-school children. Mat. American Thoracic Society, Toronto. 2000, 212, 222.
7. Biswas P. i wsp.: Montelukast and improvement of eczema: observations from a prescription event monitoring study in England. Int. J. Clin. Pharmacol. Ther., 2001, 39, 529-533.
8. Dahlen S. E.: Pharmacological characterization of leukotriene receptors. Am. J. Respir. Crit. Care Med., 2000, 161, 41-45.
9. Edelman, J.M. i wsp.: Effectiveness and safety of montelukast, a leukotriene receptor antagonist, compared to inhaled cromolyn in moderate asthmatic children. J. Allergy Clin. Immunol., 1999, 103, 1, 134.
10. Erbagci Z.: The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study.
11. Hamid Q. i wsp.: Inflammatory cells in asthma: Mechanism and implications for therapy. J. Allergy Clin. Immunol., 2003, 111, 5-17.
12. Henderson W.R. i wsp.: A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am. J. Respir. Crit. Care Med., 2002, 165, 108-116.
13. Janhz-Różyk K., Płusa T.: Leukotrieny i ich inhibitory w zapaleniu alergicznym. W: Immunoterapia chorób układu oddechowego. (red. Płusa T.). Medpress, Warszawa. 2000, 145-154.
14. Janhz-Różyk K., Mierzejewska-Zawisza J.: Leki przeciwleukotrienowe. W: Astma oskrzelowa i przewlekła obturacyjna choroba płuc. (red. Płusa T., Jahnz-Różyk K.). Medpress, Warszawa. 2001, 185-192.
15. Jung A. i wsp.: Spirometryczna ocena wyników leczenia montelukaslem u dzleci chorych na astmȩ oskrzelowa̧. Pol. Merk. Lek., 2002, 12, 68, 92.
16. Knorr B.A. i wsp.: Montelukast (MK-0476) improves asthma over a 3 months treatment period in 2- to 5-years olds. Mat. American Thoracic Society, Toronto. 2000, 56, 194.
17. Kuna P.: Leki antyleukotrienowe w chorobach alergicznych - działanie przeciwzapalne. Terapia, 2003/2, 3, 46-51.
18. Pizzichini E. i wsp.: Montelukast reduces airway eosinophilic inflamation in asthma: erandomized, contolled trial. Eur. Respir. J., 1999, 14, 12-18.
19. Pullerits T. i wsp.: Comparison of a nasal glucocorticoid, antileukotriene and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis.
20. Sak I., Kurzawa R., Doniec Z.: Leki antyleukotrienowe w leczeniu astmy oskrzelowej u dzieci. Stand. Med., 2001, 9, 3-7.
21. Samuelson B.: The discovery of the leukotrienes. Am. J. Respir. Crit. Care Med., 2000, 161, 2-6.
22. Simons E. i wsp.: Montelukast added to budesonide in children with persistent asthma: a randomized, double blind, crossover study. J. Pediatr., 2001, 138, 694-698.
23. Yokomizo T. i wsp.: A second leukotriene B4 receptor, BLT2: A new therapeutic target in inflammation and immunological disorders. J. Exp. Med., 2000, 192, 3, 421-431.
24. Yamaoka K.A. i wsp.: Leukotriene B4 enhances IL-4 induced IgE production from normal human limphocytes. Cell Immunol., 1994, 156, 124-134.